Cytek Biosciences, Inc. (CTKB)

NASDAQ: CTKB · IEX Real-Time Price · USD
11.28
-0.57 (-4.81%)
Dec 9, 2022 4:00 PM EST - Market closed
-4.81%
Market Cap 1.60B
Revenue (ttm) 154.59M
Net Income (ttm) 1.32M
Shares Out 134.71M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE 370.37
Dividend n/a
Ex-Dividend Date n/a
Volume 479,499
Open 11.78
Previous Close 11.85
Day's Range 11.24 - 11.82
52-Week Range 7.38 - 19.68
Beta n/a
Analysts Buy
Price Target 16.66 (+47.7%)
Earnings Date Nov 9, 2022

About CTKB

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The comp... [Read more]

Industry Medical Devices
IPO Date Jul 23, 2021
CEO Wenbin Jiang
Employees 574
Stock Exchange NASDAQ
Ticker Symbol CTKB
Full Company Profile

Financial Performance

In 2021, CTKB's revenue was $127.95 million, an increase of 37.82% compared to the previous year's $92.84 million. Earnings were $3.00 million, a decrease of -84.54%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CTKB stock is "Buy." The 12-month stock price forecast is 16.66, which is an increase of 47.70% from the latest price.

Price Target
$16.66
(47.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cytek Biosciences to Participate in the Piper Sandler Healthcare Conference

FREMONT, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming Piper Sandle...

2 weeks ago - GlobeNewsWire

Cytek® Biosciences Introduces Cytek Cloud

New Digital Ecosystem Supports Full Spectrum Flow Cytometry Research – from Panel Design to Data Acquisition New Digital Ecosystem Supports Full Spectrum Flow Cytometry Research – from Panel Design to D...

3 weeks ago - GlobeNewsWire

Cytek Biosciences, Inc. (CTKB) Q3 Earnings Surpass Estimates

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 100% and 6.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Cytek Biosciences Reports Third Quarter 2022 Financial Results

Third quarter revenue grew 18% compared to prior year quarter

1 month ago - GlobeNewsWire

Cytek® Biosciences Names Chris Williams Chief Operating Officer

Experienced Biotech, Pharmaceutical Industry Leader to Guide Operations Growth and Scalability

1 month ago - GlobeNewsWire

Cytek Biosciences to Report Third Quarter 2022 Financial Results on November 9, 2022

FREMONT, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2022 af...

1 month ago - GlobeNewsWire

Cytek to Participate in the 31st Annual Credit Suisse Healthcare Conference

FREMONT, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming 31st Annual ...

1 month ago - GlobeNewsWire

Cytek to Participate in the 20th Annual Morgan Stanley Global Healthcare Conference

FREMONT, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming 20th Annual ...

3 months ago - GlobeNewsWire

Cytek Biosciences, Inc. (CTKB) Q2 Earnings Surpass Estimates

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 50% and 2.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Cytek Biosciences Reports Second Quarter 2022 Financial Results

Second quarter revenue grew 32% compared to prior year Second quarter revenue grew 32% compared to prior year

3 months ago - GlobeNewsWire

Cytek to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference

FREMONT, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming 42nd Annual ...

4 months ago - GlobeNewsWire

Cytek Biosciences to Report Second Quarter 2022 Financial Results on August 10, 2022

FREMONT, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the second quarter 2022 a...

4 months ago - GlobeNewsWire

Cytek Biosciences to Host Inaugural Analyst and Investor Day

FREMONT, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) announced today that it will host its inaugural Analyst and Investor Day on We...

6 months ago - GlobeNewsWire

Cytek® Biosciences Receives CE Marking for Series of cFluor® Reagents, TBNK Kit

Company Moves to Make Total Cell Analysis Solutions Available for Clinical Applications in the European Market Company Moves to Make Total Cell Analysis Solutions Available for Clinical Applications in ...

6 months ago - GlobeNewsWire

Cytek Biosciences Reports First Quarter 2022 Financial Results

First quarter revenue grew 44% compared to prior year First quarter revenue grew 44% compared to prior year

6 months ago - GlobeNewsWire

Cytek Biosciences to Report First Quarter Financial Results on May 11, 2022

FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2022 a...

7 months ago - GlobeNewsWire

Cytek Biosciences Appoints Todd Garland Chief Commercial Officer

Industry Seasoned Executive Joins Cytek Industry Seasoned Executive Joins Cytek

7 months ago - GlobeNewsWire

Executives Buy More Than $1B Of 4 Stocks

Although US stock futures traded lower this morning on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that ...

Other symbols: CWANOXYPCOR
8 months ago - Benzinga

Cytek Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results

2021 Revenue Increased 38% Compared to Prior Year

9 months ago - GlobeNewsWire

Boeing And 3 Other Stocks Bought By Insiders

US stocks closed mixed on Wednesday following the release of minutes from the recent Federal Reserve meeting. Investors, meanwhile, focused on some notable insider trades.

Other symbols: BAJAKKMGM
9 months ago - Benzinga

Cytek to Participate in the 42nd Annual Cowen Health Care Conference

FREMONT, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating virtually in the upcoming 42...

9 months ago - GlobeNewsWire

Cytek Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

FREMONT, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and fu...

9 months ago - GlobeNewsWire

Cytek® Biosciences Expands Fremont Headquarters, Tripling Its Manufacturing Capacity

Operations to Accommodate Increasing Demand for Cell Analysis Solutions Operations to Accommodate Increasing Demand for Cell Analysis Solutions

11 months ago - GlobeNewsWire

Cytek Biosciences, Inc. (CTKB) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Cytek Biosciences, Inc. (CTKB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreemen...

1 year ago - Zacks Investment Research

Cytek® Biosciences Marks Milestone Achievement with Shipment of 1000th Cell Analysis System

Company Continues Forward Momentum Following IPO, Expanded Product Portfolio and Increased Global Footprint Company Continues Forward Momentum Following IPO, Expanded Product Portfolio and Increased Glo...

1 year ago - GlobeNewsWire